Jose Baselga - Bristol Myers Independent Director

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

  Director
Dr. Jose Baselga, M.D. Ph.D., is Independent Director of the Company. Dr. Baselga has served as PhysicianinChief of Memorial SloanKettering Cancer Center since January 2013. He has also served as Professor of Medicine at Weill Cornell Medical College and as Attending Physician, Department of Medicine and member, Human Oncology and Pathogenesis Program at MSKCC since January 2013. Previously, Dr. Baselga served as Chief of Division of Hematology Oncology and Associate Director of the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School from January 2010 to December 2012 and President of the American Association for Cancer Research from 2016 to 2017. He also served in various roles at Vall dHebron University Hospital in Barcelona, Spain, including as Founding Director, Vall dHebron Institute of Oncology from 2007 to 2012 and Director, Division of Medical Oncology, Hematology Radiation Oncology and Founding Director and Chairman, Medical Oncology Service from 1996 to 2010. Dr. Baselga also serves on the Board of Foghorn Therapeutics and Breast International Group. He is a cofounder of Tango Therapeutics. He previously served as a Director of Aura Biosciences, Inc. Dr. Baselga was a Director on the Board of Grail, Inc. until March 2018 and continues to serve as Chairman of its Scientific Advisory Board. Dr. Baselga also sits on the Advisory Boards of Aura Biosciences, Inc., Northern Biologics, Inc., Robert H. Lurie Comprehensive Cancer Center at Northwestern University and Siteman Cancer Center, Washington University at St. Louis. He previously served on the Advisory Board of Juno Therapeutics Inc. until 2018
Age: 57  Director Since 2018      
212 546-4020  www.bms.com
Baselga is an internationally recognized physician scientist who brings over 30 years of oncology experience to the Board.

Bristol Myers Management Efficiency

Bristol Myers Squibb has Return on Asset of 5.82 % which means that on every $100 spent on asset it made $5.82 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 3.0 %, implying that it generated $3.0 on every 100 dollars invested. Bristol Myers management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Return on Investment is likely to grow to 15.40 in 2020. Return on Average Assets is likely to grow to 0.07 in 2020Bristol Myers Total Assets are fairly stable at the moment as compared to the past year. Bristol Myers reported Total Assets of 129.94 Billion in 2019. Assets Non Current is likely to grow to about 108.5 B in 2020, whereas Current Assets are likely to drop slightly above 24.5 B in 2020. Bristol Myers Total Liabilities is fairly stable at the moment as compared to the past year. Bristol Myers reported Total Liabilities of 78.25 Billion in 2019. Liabilities Non Current is likely to grow to about 64.7 B in 2020, whereas Current Liabilities is likely to drop slightly above 15.2 B in 2020.
The company has 47.53 B in debt with debt to equity (D/E) ratio of 0.95, which is OK given its current industry classification. Bristol Myers Squibb has a current ratio of 1.63, which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

DIRECTOR Since

Rochelle LazarusMerck Company
2004
Ralph AlvarezEli Lilly And
2009
Paul RothmanMerck Company
2015
Srikant DatarNovartis AG
2003
Eugene WashingtonJohnson Johnson
2012
Mary CoeMerck Company
2019
Ian DavisJohnson Johnson
2010
Charles PrinceJohnson Johnson
2006
Deryck MaughanGlaxoSmithKline PLC
2013
Mary BeckerleJohnson Johnson
2015
Nicholas MooreGilead Sciences
2004
Gayle WilsonGilead Sciences
2001
Steven MayerGrifols S A
2016
Jesse GoodmanGlaxoSmithKline PLC
2017
Elizabeth DohertyNovartis AG
2016
Nuria LapenaGrifols S A
2015
Raul AlvarezEli Lilly And
2009
Nazneen RahmanAstrazeneca PLC
2017
Wendell WeeksMerck Company
2004
Andreas PlantaNovartis AG
2006
Julian GangolliGW Pharmaceuticals Plc
2015

Company Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 30000 people.Bristol Myers Squibb (BMY) is traded on BATS Exchange in USA. It is located in 430 E. 29th Street 14th Floor, New York, NY 10016, United States and employs 30,000 people. Bristol Myers is listed under Pharmaceutical Products category by Fama And French industry classification.

Bristol Myers Squibb Leadership Team

Ann Powell, Chief Human Resource Officer, Senior Vice President
Togo West, Independent Director
Karen Vousden, Independent Director
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer
Michael Bonney, Independent Director
Alan Lacy, Independent Director
Robert Bertolini, Independent Director
Jose Baselga, Independent Director
Charles Bancroft, Chief Financial Officer, Executive Vice President - Global Business Operations
Gerald Storch, Independent Director
Louis Schmukler, Executive Vice President, President - Global Product Development and Supply
Michael Grobstein, Independent Director
Christopher Boerner, Executive Vice President and Chief Commercial Officer
Phyllis Yale, Independent Director
John Elicker, Senior Vice President - Corporate Affairs and Investor Relations
David Elkins, Executive Vice President and Chief Financial Officer Member of the Leadership Team
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer
Karen Santiago, Senior Vice President, Corporate Controller
Rupert Vessey, Executive Vice President Research and Early Development Member of the Leadership Team
Giovanni Caforio, Chairman of the Board, Chief Executive Officer
Vicki Sato, Lead Independent Director
Emmanuel Blin, Senior Vice President Chief Strategy Officer
Nadim Ahmed, Executive Vice President and President - Hematology
Joseph Caldarella, Senior Vice President Corporate Controller
Julia Haller, Independent Director
Laurie Glimcher, Independent Director
Murdo Gordon, Executive Vice President Chief Commercial Officer
Lamberto Andreotti, Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. Committee
Joseph Eid, Senior Vice President and Head of Global Medical Affairs Member of the Leadership Team
Thomas Lynch, Chief Scientific Officer, Executive Vice President
Lewis Campbell, Independent Director
Dinesh Paliwal, Independent Director
Theodore Samuels, Independent Director
Samuel Moed, Senior Vice President - Strategic Planning and Analysis
Matthew Emmens, Independent Director
Ann Judge, Chief Human Resource Officer, Senior Vice President Member of the Leadership Team
Sandra Leung, Executive Vice President, General Counsel
Paul Autenried, Chief Information Officer, Senior Vice President
Samit Hirawat, Executive Vice President Chief Medical Officer, Global Drug Development Member of the Leadership Team
Tim Power, Vice President of Investor Relations
Francis Cuss, Executive Vice President Chief Scientific Officer
Paul Biondi, Senior Vice President, Head of Strategy & Business Development
Kathryn Metcalfe, Executive Vice President - Corporate Affairs Member of the Leadership Team
Peter Arduini, Independent Director
Elizabeth Mily, Executive Vice President - Strategy & Business Development

Stock Performance Indicators

Current Sentiment - BMY

Bristol Myers Squibb Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Bristol Myers Squibb. What is your opinion about investing in Bristol Myers Squibb? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Bristol Myers Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myers and Gilead Sciences. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page